Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel ME (2022)
Publication Type: Journal article, Review article
Publication year: 2022
This review describes neuroendocrine neoplasms (NEN) classification, incidence, pathogenesis, and current management, focusing on delta-like ligand 3 (DLL3) in NEN progression and prognosis. Therapeutic targeting of DLL3 is addressed, and ongoing studies of DLL3-targeting therapies are summarized.
APA:
Yao, J., Bergsland, E., Aggarwal, R., Aparicio, A., Beltran, H., Crabtree, J.S.,... Pavel, M.E. (2022). DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. https://doi.org/10.1093/oncolo/oyac161
MLA:
Yao, James, et al. "DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms." Oncologist (2022).
BibTeX: Download